Categories: Health

Humacyte to Present at the 34th Annual Piper Sandler

Published by
Globe News Wire


DURHAM, N.C., Nov. 23, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, and Dale Sander, Chief Financial Officer, will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference taking place at the Lotte New York Palace in New York, NY, on Thursday, December 1, 2022 at 12 PM ET.

Access the live webcast here. A replay will be available for at least 30 days following the presentation at https://investors.humacyte.com/news-events/events-and-presentations.

About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and complex tissue and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAV for arteriovenous (AV) access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Elizabeth Miller, M.D.
LifeSci Communications LLC
+1-646-791-9705
emiller@lifescicomms.com

Globe News Wire
Share
Published by
Globe News Wire

Recent Posts

Reebok Debuts New Human Rights Now! Collection with Lexie Brown to Bring Awareness to Equity and Access in Sport

In Conjunction with Collection Launch, Reebok to Donate $600,000 to RISE, a national nonprofit that… Read More

11 mins ago

IOC EB receives updates on activities of NOCs

06 Dec 2022 - During its meeting today, the Executive Board (EB) of the International… Read More

28 mins ago

Plastic Dielectric Films Market Size is expected to reach

BEIJING, Dec. 06, 2022 (GLOBE NEWSWIRE) -- The Global Plastic Dielectric Films Market Size accounted… Read More

30 mins ago

X4 Pharmaceuticals Announces Proposed Public Offering

BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in… Read More

32 mins ago

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Spectrum Pharmaceuticals, Inc. (SPPI)

SAN DIEGO--(BUSINESS WIRE)--$SPPI #FDA--The Class: Robbins LLP informs investors that a shareholder filed a class… Read More

33 mins ago

Energy Storage Systems Market Size Will Attain USD 394.3

TOKYO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- The Global Energy Storage Systems Market Size accounted… Read More

2 hours ago